Legal Calls sells exclusive Dupixent leads and signed retainers to law firms. Claimants allege Dupixent (dupilumab) caused or accelerated cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome. Leads come from our own Meta, TikTok and Google ads, are screened by our in-house intake team, and are delivered by CRM, API, email or warm transfer.
| Case type | Pharmaceutical product liability (dupilumab) |
| Litigation | MDL No. 3180, D.N.J., Judge Zahid N. Quraishi (created June 4, 2026) |
| Alleged injuries | Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome |
| Lead sources | Meta, TikTok & Google ads — no affiliates |
| What you get | Exclusive leads or signed retainers |
| Delivery | CRM, API, email or warm transfer |
| Intake | In-house team, under 1-minute speed-to-lead |
| Proof | TrustedForm certificate, call recordings, ad account access |
| Volume | On request |
| Last reviewed | November 2026 |
On June 4, 2026 the JPML created MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi. About 15 actions were centralized at the start. Defendants include Regeneron Pharmaceuticals and Sanofi-Aventis U.S. LLC.
The Panel did not decide whether T-cell lymphomas other than CTCL belong in the MDL. The FDA listed Dupixent and CTCL as a potential signal of serious risk in its adverse event reporting system report for October-December 2024, published in 2025. The Dupixent label does not carry a lymphoma warning.
As of November 2026 the MDL is at an early stage. The initial case management conference was held October 1, 2026, plaintiffs’ leadership was appointed in October, and a November 2, 2026 order set phased discovery starting with general causation, running into 2028. About 40 actions were pending as of early November 2026. No bellwether schedule or settlement had been reported.
Sources: Dupixent MDL Created in New Jersey (Weitz & Luxenberg) · JPML Centralizes Actions Alleging Link Between Dupixent, T-Cell Lymphoma (HarrisMartin) · Dupixent Lawsuit (King Law) · Dupixent Lawsuit News: MDL 3180 Docket Updates (Marin Murphy). Status as of November 2026.
Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.
Exclusive Dupixent leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.
Signed Dupixent retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.
Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.
Yes. MDL No. 3180 was created on June 4, 2026 in the District of New Jersey before Judge Zahid N. Quraishi.
Cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome, diagnosed after Dupixent use began. Whether other T-cell lymphomas belong in the MDL has not been decided.
No. Eczema is the main reason people take Dupixent. Intake instead screens out lymphoma diagnosed before Dupixent was started.
Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.
Yes. Firms can buy exclusive leads or signed retainers, priced as a percentage of ad spend or a fixed price per signed retainer.
Early. As of November 2026 the MDL had appointed plaintiffs’ leadership and set phased discovery starting with general causation, with no bellwether schedule or settlement.
Keytruda Leads · Ozempic Leads · Oxbryta Leads · Mass Tort Intake · All mass tort case leads
Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.
Book a time with our VP, and he’ll walk you through pricing and strategy step by step.